- | Ikena Oncology
What’s in a name? Biotech companies look to stand out from the crowd
Ikena Oncology changed its name in late 2019 after a three-month deliberation process; the company previously went by Kyn Therapeutics.
- | Windtree Therapeutics
How the U.S. Military Primed Windtree CEO Craig Fraser for C-Suite Success
Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.
- | OncoSec
Tumor-Agnostic Therapy for Anti-PD-1 Nonresponders
OncoSec Medical’s Tavo, a DNA-based interleukin-12 immunotherapy that is delivered to tumors via electroporation, is currently in Phase II trials
- | Scynexis
Scynexis Announces Launch Plans for Ibrexafungerp
Scynexis announced it will commercially launch its Brexafemme (ibrexafungerp) therapy in the 3rd quarter of 2021 at a media event today. The company plans a full marketing rollout for its launch in the coming months.
- | OncoSec
Outsmarting cancer with RNA, ‘genome-tuning’ drugs and other gene-altering therapies
OncoSec’s DNA-delivery system is designed to prompt the body to make more of its own IL-12. “The DNA essentially co-opts the cell’s function to cause it to make IL-12,” explained Daniel O’Connor, former CEO of OncoSec, in an interview.
- | OSE Immunotherapeutics
The hunt for a coronavirus super shot
A so-called multivalent vaccine might protect against all Covid-19 mutations and any future pathogen from the betacoronavirus family
- | TFF Pharmaceuticals
Inhaled mAb therapy against COVID-19 in the works: ‘The product is not dependent on cold chain distribution and storage’
Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.
- | TFF Pharmaceuticals
BRIEF—Firms work on inhalable antibody therapy for COVID-19
Following a collaboration agreement in November 2020, Augmenta Bioworks and TFF Pharmaceuticals have selected AUG-3387 as their lead candidate in COVID-19.
